IN2014MN01795A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01795A
IN2014MN01795A IN1795MUN2014A IN2014MN01795A IN 2014MN01795 A IN2014MN01795 A IN 2014MN01795A IN 1795MUN2014 A IN1795MUN2014 A IN 1795MUN2014A IN 2014MN01795 A IN2014MN01795 A IN 2014MN01795A
Authority
IN
India
Prior art keywords
patient
biological fluid
percentage
bcl2l10 protein
sample
Prior art date
Application number
Inventor
Thomas Cluzeau
Patrick Auberger
Guillaume Robert
Frédéric Luciano
Original Assignee
Université Nice Sophia Antipolis
Ct Hospitalier Universitaire Nice
Inst Nat Santé Et De La Rech Médicale Inserm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Nice Sophia Antipolis, Ct Hospitalier Universitaire Nice, Inst Nat Santé Et De La Rech Médicale Inserm filed Critical Université Nice Sophia Antipolis
Publication of IN2014MN01795A publication Critical patent/IN2014MN01795A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)

Abstract

The invention relates to an analysis method for predicting resistance to azacitidine treatment in a patient using the BCL2L10 protein contained in a sample of biological fluid taken from said patient and also biological molecules which specifically bind the BCL2L10 protein. It is characterized in that a sample of biological fluid is recovered from a patient; the percentage of total cells in said biological fluid expressing the BCL2L10 protein is calculated; this calculated percentage is compared with a reference threshold value this threshold value being between 20% and 60%; and resistance to azacitidine treatment is diagnosed in a patient who has a percentage of cells expressing the BCL2L10 protein in said biological fluid which is greater than said reference value.
IN1795MUN2014 2012-02-28 2013-02-28 IN2014MN01795A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1200584A FR2987446B1 (en) 2012-02-28 2012-02-28 DIAGNOSTIC TEST FOR RESISTANCE TO AZACITIDINE
PCT/FR2013/000055 WO2013128089A1 (en) 2012-02-28 2013-02-28 Test for diagnosing resistance to azacitidine

Publications (1)

Publication Number Publication Date
IN2014MN01795A true IN2014MN01795A (en) 2015-07-03

Family

ID=48083449

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1795MUN2014 IN2014MN01795A (en) 2012-02-28 2013-02-28

Country Status (11)

Country Link
US (1) US20150094217A1 (en)
EP (1) EP2820417A1 (en)
JP (1) JP6273552B2 (en)
CN (1) CN104321649A (en)
AU (1) AU2013224832A1 (en)
BR (1) BR112014021173A2 (en)
CA (1) CA2865684A1 (en)
FR (1) FR2987446B1 (en)
IL (1) IL234332A0 (en)
IN (1) IN2014MN01795A (en)
WO (1) WO2013128089A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3042650B1 (en) * 2014-03-27 2020-06-10 Palacky University, Olomouc Bromodomain inhibitor jq1 in combination with dna methylation inhibitor dac for use in cancer treatment
FR3048698B1 (en) * 2016-03-11 2021-03-05 Univ Claude Bernard Lyon BCL2 L10 INTERACTION INHIBITORS / IP3 RECEIVER
WO2019077080A1 (en) * 2017-10-19 2019-04-25 Universite Claude Bernard Lyon 1 Evaluation of the risk of metastatic relapse in breast cancer patients
CN114874987A (en) * 2022-03-01 2022-08-09 洛阳市中心医院（郑州大学附属洛阳中心医院） Myelodysplastic syndrome drug-resistant cell model and construction method and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005078100A1 (en) * 2004-02-13 2005-08-25 Bml, Inc. Method of detecting cancer cell acquiring drug-resistance
ES2550614T3 (en) * 2004-04-09 2015-11-11 Genomic Health, Inc. Gene expression markers to predict the response to chemotherapy
WO2010045651A1 (en) * 2008-10-17 2010-04-22 Nodality, Inc. Methods for analyzing drug response
CN101632643A (en) * 2009-08-18 2010-01-27 杭州咸达医药科技有限公司 Azacitidine freeze-drying powder injection and preparation method thereof
JP5190477B2 (en) * 2010-02-22 2013-04-24 譲治 稲澤 Method for detecting lung cancer cells that have acquired drug resistance to camptothecins against anticancer drugs
ES2656962T3 (en) * 2010-05-27 2018-03-01 Inserm - Institut National De La Santé Et De La Recherche Médicale Methods to assess the receptivity of a patient's endometrium

Also Published As

Publication number Publication date
JP6273552B2 (en) 2018-02-07
FR2987446B1 (en) 2016-01-01
IL234332A0 (en) 2014-10-30
FR2987446A1 (en) 2013-08-30
CA2865684A1 (en) 2013-09-06
WO2013128089A1 (en) 2013-09-06
US20150094217A1 (en) 2015-04-02
AU2013224832A1 (en) 2014-10-16
AU2013224832A8 (en) 2014-11-13
CN104321649A (en) 2015-01-28
BR112014021173A2 (en) 2017-08-22
JP2015513369A (en) 2015-05-11
EP2820417A1 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
ZA201903597B (en) Biosensors for biological or chemical analysis and methods of manufacturing the same
CY1120434T1 (en) IL-1 ACCUMULATION PROTEINS
WO2013190075A3 (en) Specific biomarkers for hepatocellular carcinoma (hcc)
EA201590247A1 (en) ANTIBODIES TO SIGLEC-15
SG10201903822XA (en) Method for the enrichment of circulating tumor dna
EP3076949A4 (en) Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
PL2986735T3 (en) Method for identifying the quantitative composition of blood cells in a sample
MX2016011377A (en) Method for diagnosing colorectal cancer from a human feces sample by quantitive pcr, primers and kit.
WO2012094580A3 (en) Compounds that modulate oxidative stress
WO2012122564A3 (en) Diagnostic and sample preparation devices and methods
EP2813854A4 (en) Hemolysis reagent composition for hemoglobin a1c quantitative analysis using enzymatic method
MX357429B (en) Predictors for cancer treatment.
EP3287791A4 (en) Method for evaluating coagulation ability of blood specimen, and reagent, reagent kit and device to be used therein
IN2014MN01795A (en)
EP2569635A4 (en) Methods for diagnosing and treating encephalitis or epilepsy
EP2909589A4 (en) Ultrasonic biological sample analysis apparatus and methods
SG11201700876RA (en) Methods and compositions for analyzing glucose-6-phosphate dehydrogenase activity in blood samples
WO2014053996A3 (en) Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs
MX2021009528A (en) Rgma fragment based diagnostic assay.
HUE043360T2 (en) Container for determining of analytes and/or chemico-physical parameters, as well as determining of urinary sediment, in urine; and method of full urine analysis using this container
HK1183064A1 (en) Sandwich immuno-pcr detection method and kit of analyte in biological samples pcr
EP2732288A4 (en) Biological microchip for the estimation of immunoglobulin e and g levels in human blood, method of assay thereof, and reagent kit comprising same
ZA201402460B (en) Assembly for determining the presence or absence of an analyte in a blood sample and analysis unit comprising such an assembly
MX2015011804A (en) Methods and compositions for diagnosing preeclampsia.
WO2013077814A3 (en) Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy